Bionano Genomics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $28.5M | $30.8M | $36.1M | $27.8M | $18.0M |
| Operating income | -$33.3M | -$104.0M | -$215.2M | -$131.7M | -$77.1M |
| Cost of revenue | $15.3M | $30.4M | $26.6M | $21.9M | $14.1M |
| Cash from operations | -$16.3M | -$68.9M | -$125.2M | -$124.8M | -$71.9M |
| Capital expenditure | — | $0 | $6,000 | $90,000 | $0 |
| Free cash flow | — | -$68.9M | -$125.2M | -$124.9M | -$71.9M |
| Impairments | $0 | $19.7M | $77.3M | $0 | $0 |
| Total assets | $73.6M | $76.7M | $214.4M | $307.5M | $377.1M |
| Total liabilities | $29.2M | $41.3M | $118.2M | $58.1M | $40.0M |
Shares outstanding 11.5M · Free float 50.4%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.